CDC/VSD-affiliated analysis of VAERS reports: 1,626 confirmed myocarditis cases after 354.1 million mRNA doses, with the highest verified reporting rates in adolescent and young adult males after dose two; 96% were hospitalized and no verified deaths under 30 were identified.
myocarditis rates were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine) and in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine)
JAMA 2022;327(4):331-340 (PMC full text)
CDC/VSD-affiliated analysis of VAERS reports: 1,626 confirmed myocarditis cases after 354.1 million mRNA doses, with the highest verified reporting rates in adolescent and young adult males after dose two; 96% were hospitalized and no verified deaths under 30 were identified. PMID 35076665. Review was performed by CDC-affiliated authors using federal surveillance data; it is the CDC-published rate series the book references.